Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study

被引：2
|
作者：
Lee, C. [1 ]
Tang, Y. [1 ]
Schroeder, C. [1 ]
Zhang, J. [1 ]
Nguyen-Cleary, T. [1 ]
Mullin, S. [1 ]
Ma, M. [1 ]
Lyon, N. [1 ]
Grundy, J. [1 ]
机构：
[1] Arena Pharmaceut Inc, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.415
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P291
引用
收藏
页码：S321 / S322
页数：4
相关论文
共 50 条
  • [41] An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment
    Nakamaru, Yoshinobu
    Kakubari, Masae
    Yoshida, Kaori
    Akimoto, Makoto
    Kondo, Kazuoki
    [J]. CLINICAL THERAPEUTICS, 2020, 42 (09) : 1699 - 1714
  • [42] A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
    Ou, Ying C.
    Preston, Richard A.
    Marbury, Thomas C.
    Tang, Zhiyu
    Novotny, William
    Tawashi, Manal
    Li, Ta-Kai
    Sahasranaman, Srikumar
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1355 - 1363
  • [43] Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study
    Dahlke, Marion
    Halabi, Atef
    Canadi, Jasna
    Tsubouchi, Chiaki
    Machineni, Surendra
    Pang, Yinuo
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (04): : 474 - 483
  • [44] A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
    Gao, Ling
    Yamamiya, Ikuo
    Pinti, Mark
    Rondon, Juan Carlos
    Marbury, Thomas
    Tomlinson, Gareth
    Makris, Lukas
    Hangai, Nanae
    Wacheck, Volker
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (09): : 1713 - 1724
  • [45] Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment
    Kuipers, Mirjam
    Smulders, Ronald
    Krauwinkel, Walter
    Hoon, Timothy
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 102 (04) : 405 - 412
  • [46] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Magda S. C. Fontes
    Jasper Dingemanse
    Atef Halabi
    Monika Tomaszewska-Kiecana
    Patricia N. Sidharta
    [J]. Scientific Reports, 12
  • [47] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Fontes, Magda S. C.
    Dingemanse, Jasper
    Halabi, Atef
    Tomaszewska-Kiecana, Monika
    Sidharta, Patricia N.
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [48] An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function
    Tomkinson, H. K.
    Weil, A.
    Engelhardt, E.
    Schmid, K.
    Oliver, S.
    Morris, T.
    Swaisland, H.
    Taboada, M.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 132 - 132
  • [49] A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment
    Marbury, T.
    Stonerock, R.
    Acharya, M.
    Gonzalez, M.
    Jiao, J.
    Breeding, J.
    Haqq, C.
    Molina, A.
    Tran, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S501 - S501
  • [50] Pharmacokinetics of tropifexor, a potent farnesoid X receptor agonist, are similar in subjects with mild, moderate, and severe hepatic impairment: results from a multi-centre, open-label, single-dose study
    Stringer, Rowan
    Chen, Jin
    Gu, Jessie
    Hackling, Melissa
    Shah, Bharti
    Nidamarthy, Prasanna Kumar
    Prince, William
    Woessner, Ralph
    [J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S534 - S535
12345